334 related articles for article (PubMed ID: 27919208)
1. Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Thent ZC; Zaidun NH; Azmi MF; Senin MI; Haslan H; Salehuddin R
Curr Drug Targets; 2017; 18(6):734-750. PubMed ID: 27919208
[TBL] [Abstract][Full Text] [Related]
2. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
3. Metformin suppresses CRC growth by inducing apoptosis via ADORA1.
Lan B; Zhang J; Zhang P; Zhang W; Yang S; Lu D; Li W; Dai Q
Front Biosci (Landmark Ed); 2017 Jan; 22(2):248-257. PubMed ID: 27814614
[TBL] [Abstract][Full Text] [Related]
4. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
[TBL] [Abstract][Full Text] [Related]
7. Targeting mTOR network in colorectal cancer therapy.
Wang XW; Zhang YJ
World J Gastroenterol; 2014 Apr; 20(15):4178-88. PubMed ID: 24764656
[TBL] [Abstract][Full Text] [Related]
8. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
9. Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
Saber MM; Al-Mahallawi AM; Nassar NN; Stork B; Shouman SA
BMC Cancer; 2018 Aug; 18(1):822. PubMed ID: 30111296
[TBL] [Abstract][Full Text] [Related]
10. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
[TBL] [Abstract][Full Text] [Related]
11. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
12. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
13. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
15. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
16. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits the development and metastasis of colorectal cancer.
Sugiura K; Okabayashi K; Seishima R; Ishida T; Shigeta K; Tsuruta M; Hasegawa H; Kitagawa Y
Med Oncol; 2022 Jul; 39(9):136. PubMed ID: 35780231
[TBL] [Abstract][Full Text] [Related]
18. Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production.
Mogavero A; Maiorana MV; Zanutto S; Varinelli L; Bozzi F; Belfiore A; Volpi CC; Gloghini A; Pierotti MA; Gariboldi M
Sci Rep; 2017 Nov; 7(1):15992. PubMed ID: 29167573
[TBL] [Abstract][Full Text] [Related]
19. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
20. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
